Mumbai, Nov. 9 -- BDR Pharmaceuticals International Pvt. Ltd is acquiring a controlling stake in Acme Formulation Pvt. Ltd's oral solid formulations business and its subsidiaries from existing investors, including private equity firm PAG, the companies said in a statement on Monday.

The transaction is expected to value the business at about $250 million, according to a person familiar with the matter. O3 Capital acted as the exclusive financial advisor to BDR Pharma on the transaction.

The acquisition aligns with BDR's growth priorities across oncology, critical care, and women's healthcare, while creating opportunities to expand its product offerings in international markets.

A key strategic rationale for the acquisition is the additi...